A 40-year-old Japanese female was referred to our institution with a high serum lactate dehydrogenase level. Computed tomography (CT) showed a large right adrenal tumor, 14 cm in size without distant metastases. The patient was clinically diagnosed with T2N0M0 adrenocortical carcinoma and underwent right adrenalectomy. The pathological diagnosis was adrenocortical carcinoma with negative surgical margin. The patient was administered mitotane for 2 years as adjuvant therapy. Subsequently, CT revealed asynchronous multiple metastases, including liver, lung, left kidney, and right acetabulum. The patient received 15 courses of EDP (a combination of etoposide, doxorubicin, and cisplatin) plus mitotane therapy, and had stable disease without new lesions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.14989/ActaUrolJap_68_5_139 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Editorial: Rare forms of pediatric adrenal disorders: beyond congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Front Endocrinol (Lausanne)
December 2024
Centre for Endocrinology, William Harvey Research Institute, Barts & the London School of Medicine & Dentistry, Queen Mary, University of London, London, United Kingdom.
A Histomorphologic and Ultrastructural Report of an Oncocytic Adrenal Cortical Carcinoma With Clinicoradiologic Correlates.
Cureus
November 2024
Department of Pathology and Laboratory Medicine, National Kidney and Transplant Institute, Quezon City, PHL.
Oncocytic adrenal cortical carcinoma (ACC) is a rare malignant adrenal cortical tumor with limited documented case reports. Herein, a 65-year-old female patient presented with a large, solid adrenal mass. A diagnosis of oncocytic ACC was rendered with the following tumor characteristics: The tumor entirely consists of diffuse sheets of polygonal cells with bizarre nuclear atypia and deeply eosinophilic cytoplasm.
View Article and Find Full Text PDFPan-cancer analysis combined with experimental validation revealed that is an immunological and prognostic biomarker.
Transl Cancer Res
November 2024
Department of Clinical Laboratory, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Background: Kinectin 1 () is a membrane protein involved in intracellular organelle motility. However, the role of in human pan-cancer lacks systematic analysis and evaluation. The aim of this study is to evaluate the expression profile and clinical value in human cancers by performing a pan-cancer analysis of .
View Article and Find Full Text PDFA Review on Mitotane: A Target Therapy in Adrenocortical Carcinoma.
Cancers (Basel)
December 2024
Department of Clinical Medicine and Surgery, University of Naples Federico II, 80131 Naples, Italy.
Adrenocortical carcinomas (ACCs) are rare and aggressive malignancies of adrenal cortex, associated with largely unknown mechanisms of biological development and poor prognosis. Currently, mitotane is the sole approved drug for treating advanced adrenocortical carcinomas (ACCs) and is being utilized more frequently as postoperative adjuvant therapy. Although it is understood that mitotane targets the adrenal cortex and disrupts steroid production, its precise mechanism of action requires further exploration.
View Article and Find Full Text PDFMolecular and Clinical Features of Adrenocortical Tumors in Beckwith-Wiedemann Spectrum.
Cancers (Basel)
November 2024
Department of Public Health and Pediatrics, University of Torino, 10126 Torino, Italy.
Background/objectives: Adrenocortical tumors (ACTs), including adrenocortical adenoma (ACA) and carcinoma (ACC), represent 0.3-0.4% of pediatric tumors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!